Pieris Pharmaceuticals (PIRS) Stock Analysis

What Pieris Pharmaceuticals does

Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids. The company's pipeline includes several key drug candidates: Respiratory: PRS-060/AZD1402: A lead Anticalin candidate currently in Phase II clinical trials, targeting IL-4Ra for the treatment of asthma and various inflammatory diseases. PRS-220: An orally inhaled Anticalin protein designed to target connective tissue growth factor, intended for the treatment of idiopathic pulmonary fibrosis (IPF). Immuno-Oncology: Cinrebafusp alfa: A bispecific drug targeting both 4-1BB and HER2, developed for gastric cancers that express high or low levels of HER2. PRS-344/S095012: A bispecific Anticalin-antibody fusion protein in Phase I clinical trials, targeting 4-1BB and PD-L1 for various immuno-oncology indications. PRS-352: A preclinical-stage program focusing on undisclosed targets within immuno-oncology. Pieris has established several strategic partnerships, including collaboration and licensing agreements with Les Laboratoires Servier (and Institut de Recherches Internationales Servier), AstraZeneca AB, and Seagen Inc. Further licensing agreements are in place with the Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Additionally, the company has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Established in 2000, Pieris Pharmaceuticals, Inc. maintains its headquarters in Boston, Massachusetts.

Key metrics

ETFs linked to PIRS

Broad-market and Healthcare sector ETFs an investor holding Pieris Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PIRS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Pieris Pharmaceuticals?

Pieris Pharmaceuticals trades under the ticker PIRS on NASDAQ.

Which exchange is PIRS listed on?

PIRS is listed on NASDAQ.

What sector does Pieris Pharmaceuticals operate in?

Pieris Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PIRS in a portfolio?

PortView shows PIRS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.